Disc Medicine (NASDAQ:IRON) Stock Price Expected to Rise, HC Wainwright Analyst Says

Disc Medicine (NASDAQ:IRON) had its price objective lifted by HC Wainwright from $70.00 to $118.00 in a report released on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Disc Medicine’s Q4 2024 earnings at ($0.88) EPS, FY2024 earnings at ($3.88) EPS, Q1 2025 earnings at ($1.02) EPS, Q2 2025 earnings at ($1.17) EPS, Q3 2025 earnings at ($1.33) EPS, Q4 2025 earnings at ($1.35) EPS, FY2025 earnings at ($4.87) EPS, FY2026 earnings at ($3.94) EPS, FY2027 earnings at ($3.38) EPS and FY2028 earnings at ($1.50) EPS.

A number of other research analysts have also recently issued reports on the stock. Jefferies Financial Group initiated coverage on shares of Disc Medicine in a research report on Wednesday, October 23rd. They set a “buy” rating and a $89.00 price target for the company. Scotiabank boosted their price target on Disc Medicine from $62.00 to $70.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, November 5th. Morgan Stanley raised Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective for the company in a research report on Tuesday, November 5th. Wells Fargo & Company initiated coverage on shares of Disc Medicine in a report on Thursday, August 22nd. They set an “overweight” rating and a $75.00 price target on the stock. Finally, Raymond James upgraded Disc Medicine from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the stock from $66.00 to $110.00 in a report on Monday, November 4th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $85.80.

Disc Medicine Stock Performance

Disc Medicine stock opened at $59.46 on Wednesday. Disc Medicine has a fifty-two week low of $25.60 and a fifty-two week high of $77.60. The stock’s 50 day simple moving average is $51.20 and its two-hundred day simple moving average is $45.09. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of -14.94 and a beta of 0.60.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.15. On average, analysts predict that Disc Medicine will post -4.15 earnings per share for the current year.

Insider Activity

In other news, Director William Richard White sold 7,136 shares of the firm’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 7,538 shares of company stock valued at $437,875 in the last ninety days. Corporate insiders own 4.24% of the company’s stock.

Institutional Investors Weigh In On Disc Medicine

Institutional investors have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. boosted its stake in shares of Disc Medicine by 123.5% in the second quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company’s stock worth $79,090,000 after acquiring an additional 969,834 shares during the period. Logos Global Management LP purchased a new stake in Disc Medicine during the 2nd quarter valued at approximately $41,690,000. Point72 Asset Management L.P. purchased a new position in Disc Medicine during the second quarter valued at $34,318,000. Deerfield Management Company L.P. Series C grew its position in shares of Disc Medicine by 53.8% during the second quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company’s stock valued at $46,119,000 after purchasing an additional 357,730 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Disc Medicine by 59.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 944,213 shares of the company’s stock worth $58,788,000 after acquiring an additional 353,382 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.